Here's Why Ascendis Pharma Shares Are Surging Higher Today
Shares of Ascendis Pharma (NASDAQ: ASND) are on the move following the approval of the company's first drug. Investors are more than a little excited about potential sales of the company's new once-weekly injection for human growth hormone therapy, now named Skytrofa. The stock was up 21.3% as of 1:42 p.m. EDT on Thursday.
According to Ascendis Pharma, annual U.S. spending on human growth hormone treatments works out to around $500 million from U.S. adults and another $700 million from pediatric indications.
Image source: Getty Images.
Source Fool.com
